Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
74
Recruiting, any sponsor type, condition "alcohol dependence"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed454
74 trials
Showing 1 to 25, recently updated first.
University of IowaAcademic, hospital or other
NCT06405607 · 80 participants (planned) · Start Jun 12, 2025 · Primary completion Apr 2028
Drug: Psilocybin; Ketamine · For: Alcohol Use Disorder; Alcohol Dependence; Alcohol Abuse
Sites: Iowa City, Iowa
University Hospital of North NorwayAcademic, hospital or other
NCT06090422 · 34 participants (planned) · Start Jan 20, 2025 · Primary completion Jul 1, 2028
Drug: Ketamine Hydrochloride; Midazolam Hydrochloride · For: Depression; Alcohol Use Disorder
Sites: Moss, Norway; Tromsø, Norway
National Institute on Drug Abuse (NIDA)NIH
NCT05807139 · 20 participants (planned) · Start Jul 13, 2023 · Primary completion Dec 31, 2026
Drug: Spironolactone · For: Alcohol Use Disorder
Sites: Baltimore, Maryland
University of Illinois at Urbana-ChampaignAcademic, hospital or other
NCT07125534 · 200 participants (planned) · Start Aug 9, 2025 · Primary completion Jan 2027
Drug: Alcohol beverage · For: Alcohol Drinking; Alcohol Use Disorder (AUD); Alcohol Intoxication and 3 more
Sites: Champaign, Illinois · 2 sites in all
- Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive SymptomsPivotal-lookingRecruiting
Centre Hospitalier Universitaire de NīmesAcademic, hospital or other
NCT07638553 · 172 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 2030
Drug: Psilocybin (high dose); Psilocybin (low dose) · For: Alcohol Use Disorder; Depressive Sympotoms; Psilocybin
Sites: Bayonne, France; Besançon, France; Bordeaux, France · 8 sites in all
- Sex Differences in the Response to Abstinence From Alcohol.Pivotal-lookingRecruiting
Indiana UniversityAcademic, hospital or other
NCT03827460 · 160 participants (planned) · Start Apr 10, 2019 · Primary completion Feb 28, 2027
Drug: Intravenous Alcohol · For: Alcohol Use Disorder
Sites: Indianapolis, Indiana
Institut National de la Santé Et de la Recherche Médicale, FranceGovernment (non-federal)
NCT07844720 · 60 participants (planned) · Start Nov 2, 2026 · Primary completion Oct 22, 2027
Drug: Thiamine · For: Alcohol Use Disorder
Sites: Paris, France
- Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use OutcomesRecruiting
Yale UniversityAcademic, hospital or other
NCT07772960 · 90 participants (planned) · Start Oct 1, 2026 · Primary completion Oct 31, 2031
Drug: Semaglutide 1.0 mg; Semaglutide 2.0 mg · For: Alcohol Use Disorder (AUD); Obesity (BMI Equal to or >30)
Sites: New Haven, Connecticut · 2 sites in all
- A Study of Brenipatide in Participants With Alcohol Use DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07219953 · 1,100 participants (planned) · Start Oct 16, 2025 · Primary completion Apr 2028
Drug: LY3537031; Placebo · For: Alcohol Use Disorder
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Los Angeles, California · 115 sites in all
- Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and CravingPivotal-lookingRecruiting
Johns Hopkins UniversityAcademic, hospital or other
NCT07148843 · 105 participants (planned) · Start Oct 21, 2026 · Primary completion Oct 31, 2030
Drug: Cannabidiol (CBD); Placebo · For: Alcohol Use Disorder (AUD); Withdrawal From Addictive Substance; Detoxification; Craving
Sites: Baltimore, Maryland
Rajesh NarendranAcademic, hospital or other
NCT07825818 · 100 participants (planned) · Start Sep 30, 2026 · Primary completion Dec 31, 2032
Drug: [F-18]BCPP-EF; [F-18]FDG · For: Alcohol Use Disorder (AUD); Healthy Controls Group - Age and Sex-matched
Sites: Pittsburgh, Pennsylvania
National Institute of Mental Health (NIMH)NIH
NCT07027839 · 30 participants (planned) · Start Dec 11, 2025 · Primary completion Feb 22, 2028
Drug: Intravenous Ethanol; 18F-PF-06445974 · For: Alcohol Use Disorder
Sites: Bethesda, Maryland
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
NCT06269627 · 48 participants (planned) · Start May 7, 2025 · Primary completion Dec 31, 2026
Drug: Acamprosate calcium · For: Alcohol Use Disorder
Sites: Bethesda, Maryland
Yale UniversityAcademic, hospital or other
NCT07029529 · 80 participants (planned) · Start May 12, 2026 · Primary completion Aug 2030
Drug: Apremilast 60mg · For: Alcohol Use Disorder
Sites: New Haven, Connecticut
National Institute of Mental Health (NIMH)NIH
NCT06795581 · 30 participants (planned) · Start Mar 20, 2025 · Primary completion Dec 11, 2028
Drug: 18F-PF-06445974; Oxazepam · For: Alcohol Use Disorder
Sites: Bethesda, Maryland
- Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use DisorderRecruiting
Centre for Addiction and Mental HealthAcademic, hospital or other
NCT07405606 · 30 participants (planned) · Start Mar 23, 2026 · Primary completion Mar 2028
Drug: Psilocybin 25 mg; Placebo · For: Major Depressive Disorder (MDD); Alcohol Use Disorder (AUD)
Sites: Toronto, Canada
- Suvorexant for Alcohol Use Disorder (AUD): Neural MechanismsPivotal-lookingRecruiting
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
NCT06484075 · 180 participants (planned) · Start Nov 21, 2024 · Primary completion Dec 31, 2028
Drug: Suvorexant; Placebo · For: Healthy Volunteers; Alcohol Use Disorder (AUD)
Sites: Bethesda, Maryland
- Suvorexant for Treatment of AUD and PTSDRecruiting
Pharmacotherapies for Alcohol and Substance Use Disorders AllianceAcademic, hospital or other
NCT06679062 · 76 participants (planned) · Start Jul 16, 2025 · Primary completion Mar 2027
Drug: Suvorexant · For: Alcohol Use Disorder (AUD); Post Traumatic Stress Disorder (PTSD); Insomnia
Sites: Los Angeles, California; Houston, Texas
- Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)Pivotal-lookingRecruiting
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
NCT07559500 · 176 participants (planned) · Start May 20, 2026 · Primary completion Dec 31, 2031
Drug: Tirzepatide; Placebo and 2 more · For: Alcohol Use Disorder (AUD)
Sites: Bethesda, Maryland
- LSD Treatment for Persons With Alcohol Use DisorderPivotal-lookingRecruiting
Felix MuellerAcademic, hospital or other
NCT05474989 · 128 participants (planned) · Start Jan 27, 2026 · Primary completion Oct 31, 2028
Drug: LSD; Active placebo · For: Alcohol Use Disorder (AUD)
Sites: Basel, Switzerland; Bern, Switzerland
- A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use DisorderPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07219966 · 1,100 participants (planned) · Start Oct 15, 2025 · Primary completion Apr 2028
Drug: LY3537031; Placebo · For: Alcohol Use Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 117 sites in all
- Sex Differences in Trauma, Inflammation and Brain Function and the Implications for Treatment Efficacy in Alcohol Use DisorderPivotal-lookingRecruiting
Milky KohnoAcademic, hospital or other
NCT06426303 · 100 participants (planned) · Start May 2, 2024 · Primary completion Dec 31, 2028
Drug: Naltrexone · For: Alcohol Use Disorder
Sites: Portland, Oregon
- Cannabis' Impact on Alcohol ConsumptionPivotal-lookingRecruiting
Brown UniversityAcademic, hospital or other
NCT05389930 · 350 participants (planned) · Start Mar 16, 2023 · Primary completion Aug 31, 2027
Drug: THC-dominant cannabis; CBD-dominant cannabis and 3 more · For: Alcohol Drinking; Cannabis Use; Cannabis and 1 more
Sites: Providence, Rhode Island
Brown UniversityAcademic, hospital or other
NCT05988632 · 40 participants (planned) · Start Feb 25, 2025 · Primary completion Dec 31, 2026
Drug: Regular Human Insulin then Placebo; Placebo then Regular Human Insulin · For: Alcohol Use Disorder
Sites: Providence, Rhode Island
- Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient StudyRecruiting
Pharmacotherapies for Alcohol and Substance Use Disorders AllianceAcademic, hospital or other
NCT06335407 · 10 participants (planned) · Start Jul 28, 2025 · Primary completion Feb 27, 2027
Drug: Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg; Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg · For: Alcohol Use Disorder (AUD); Post Traumatic Stress Disorder (PTSD)
Sites: West Haven, Connecticut
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.